World Pharma – Clinical Trial Insight Vol 2
Featuring: Manish Soman – Sciformix, A Covance Company
Covance’s acquisition of scientific process outsourcing company (SPO) Sciformix strengthens its position in the later phases of drug and device development, particularly post-marketing pharmacovigilance and market access solutions. We speak to Manish Soman of Sciformix about what this acquisition means for both companies.
Covance recently acquired Sciformix – can you tell us why?
Covance acquired Sciformix in the summer of 2018 to further enhance its post-marketing capabilities
and continue to grow its leadership position in drug development solutions. Covance has been expanding its offerings in the latephase/post-marketing space and seeking a greater global footprint. Over the last decade, Sciformix has proved to be best in class in both.
Additionally, with most of our employees in India and the Philippines, Sciformix extends Covance’s ability to offer its
clients a cost-optimised global delivery model. The two organisations are recognised for their commitment to
scientific and therapeutic excellence, and quality services. With Sciformix’s deep domain knowledge in the postapproval safety and risk management space, it is a welcome and strategic addition to the Covance family.
Covance acquired Chiltern in 2017 and has a history of acquiring and integrating companies into its fold that
broaden its portfolio and strengthen its ability to deliver best-in-class service capabilities. Together with Chiltern
and Sciformix, Covance will leverage their greatest strengths and support its work in transforming drug
development through innovation and greater efficiency.
Another benefit our clients will reap is enhanced innovation and operational transformation via technology and automation. For example, Sciformix has introduced some pretty neat solutions for safety in risk management, from basic and robotic automation to the fast-paced cognitive and AI technology space.